MA30959B1 - Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp - Google Patents

Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp

Info

Publication number
MA30959B1
MA30959B1 MA31938A MA31938A MA30959B1 MA 30959 B1 MA30959 B1 MA 30959B1 MA 31938 A MA31938 A MA 31938A MA 31938 A MA31938 A MA 31938A MA 30959 B1 MA30959 B1 MA 30959B1
Authority
MA
Morocco
Prior art keywords
triazole compounds
substituted pyrazole
ksp inhibitors
pharmaceutically acceptable
ksp
Prior art date
Application number
MA31938A
Other languages
English (en)
Inventor
Yi Xia
Kris G Mendenhall
Paul A Barsanti
Annette O Walter
David Duhl
Paul A Renhowe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30959B1 publication Critical patent/MA30959B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVEAUX COMPOSÉS DE PYRAZOLE ET DE TRIAZOLE SUBSTITUÉS REPRÉSENTÉS PAR LA FORMULE (I), ET DES SELS, DES ESTERS OU DES PROMÉDICAMENTS PHARMACEUTIQUEMENT ACCEPTABLES DE CEUX-CI, DES COMPOSITIONS DE CES DÉRIVÉS CONTENANT DES EXCIPIENTS PHARMACEUTIQUEMENT ACCEPTABLES AINSI QUE DES UTILISATIONS DE CELLES-CI.
MA31938A 2006-11-13 2009-06-01 Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp MA30959B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13

Publications (1)

Publication Number Publication Date
MA30959B1 true MA30959B1 (fr) 2009-12-01

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31938A MA30959B1 (fr) 2006-11-13 2009-06-01 Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp

Country Status (32)

Country Link
US (2) US7902240B2 (fr)
EP (1) EP2091926B1 (fr)
JP (1) JP5264755B2 (fr)
KR (1) KR20090081020A (fr)
CN (1) CN101558049B (fr)
AR (1) AR063805A1 (fr)
AU (1) AU2007323998B2 (fr)
BR (1) BRPI0719002A2 (fr)
CA (1) CA2668661A1 (fr)
CL (1) CL2007003272A1 (fr)
CO (1) CO6382171A2 (fr)
CR (1) CR10787A (fr)
DO (1) DOP2009000106A (fr)
EA (1) EA017748B1 (fr)
EC (1) ECSP099326A (fr)
ES (1) ES2557478T3 (fr)
GE (1) GEP20125389B (fr)
GT (1) GT200900122A (fr)
HN (1) HN2009000968A (fr)
IL (1) IL198471A0 (fr)
MA (1) MA30959B1 (fr)
MX (1) MX2009005071A (fr)
NI (1) NI200900084A (fr)
NO (1) NO20092226L (fr)
NZ (1) NZ576640A (fr)
PE (1) PE20081169A1 (fr)
SM (1) SMP200900045B (fr)
TN (1) TN2009000178A1 (fr)
TW (1) TW200831480A (fr)
UA (1) UA97256C2 (fr)
WO (1) WO2008063912A1 (fr)
ZA (1) ZA200902940B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2091926B1 (fr) * 2006-11-13 2015-10-21 Novartis AG Composés de pyrazole et de triazole substitués comme inhibiteurs de ksp
WO2008086122A2 (fr) * 2007-01-05 2008-07-17 Novartis Ag Dérivés cyclisés en tant qu'inhibiteurs d'eg-5
EA201201404A1 (ru) * 2010-04-15 2013-04-30 Новартис Аг Триазолы как ингибиторы кбв (кинезин-белок веретена)
WO2011128388A2 (fr) * 2010-04-15 2011-10-20 Novartis Ag Composés d'oxazole et de thiazole comme inhibiteurs de ksp
EP2928472B1 (fr) * 2012-12-05 2018-05-02 Merck Sharp & Dohme Corp. Procédé de préparation d'inhibiteurs de transcriptase inverse
EP2968591A1 (fr) * 2013-03-15 2016-01-20 Novartis AG Inhibiteurs de la prolifération cellulaire et leurs conjugués
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
BR112016012658B1 (pt) 2013-12-04 2022-06-21 Merck Sharp & Dohme Corp Métodos para sintetizar inibidores da transcriptase reversa e composto
WO2016020791A1 (fr) 2014-08-05 2016-02-11 Novartis Ag Conjugués anticorps ckit-médicament
WO2017097927A1 (fr) * 2015-12-11 2017-06-15 Syngenta Participations Ag Dérivés de 1,2,4-triazole actifs à action pesticide
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) * 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
CA2369549A1 (fr) 1999-04-02 2000-10-12 Robert W. Desimone Derives d'aminoalkyle-imidazole condenses aryles et heteroaryles et leur utilisation comme antidiabetiques
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CZ20021428A3 (cs) 1999-10-27 2002-11-13 Cytokinetics, Inc. Způsoby a kompozice vyuľívající chinazoliny
MXPA03003039A (es) 2000-10-06 2003-10-15 Neurogen Corp Derivados de indola y bencimidazola como moduladores del receptor crf.
WO2002057244A1 (fr) 2001-01-19 2002-07-25 Cytokinetics, Inc. Inhibiteurs de la kinesine a base de phenothiazine
EP1351671A1 (fr) 2001-01-19 2003-10-15 Cytokinetics, Inc. Inhibiteurs triphenylmethane de la kinesine
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
WO2003039480A2 (fr) 2001-11-08 2003-05-15 The University Of Chicago Methode de traitement de troubles lies a un taux de cholesterol eleve
WO2003043995A1 (fr) 2001-11-20 2003-05-30 Cytokinetics, Inc. Procede de racemisation de quinazolinones chirales
CA2467722A1 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
CA2468156A1 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs mitotiques de la kinesine
WO2003049527A2 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs miotitiques de la kinesine
US20050107404A1 (en) 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
EP1461027A4 (fr) * 2001-12-07 2005-09-07 Univ Virginia Commonwealth Traitement de la neoplasie
WO2003059289A2 (fr) 2002-01-10 2003-07-24 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue
JP2005529076A (ja) 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
EP1553931A4 (fr) 2002-05-09 2006-08-30 Cytokinetics Inc Composes, compositions et procedes
RU2004135554A (ru) 2002-05-09 2006-01-20 Цитокинетикс, Инк. (Us) Пиримидиноны, композиции на их основе и способы их использования
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
EP1509507A4 (fr) 2002-05-23 2006-09-13 Merck & Co Inc Inhibiteurs de kinesine mitotique
EP1513820A4 (fr) 2002-05-23 2006-09-13 Cytokinetics Inc Composes, compositions et procedes
ATE356804T1 (de) 2002-06-14 2007-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
EP1515724B1 (fr) 2002-06-14 2009-10-21 Merck & Co., Inc. Inhibiteur de kinesines mitotiques
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
DE60326248D1 (de) 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
EP1537089A4 (fr) 2002-07-23 2008-04-16 Cytokinetics Inc Composes, compositions et procedes
WO2004018058A2 (fr) 2002-08-21 2004-03-04 Cytokinetics, Inc. Composes, compositions et methodes
EP1554265A4 (fr) 2002-09-13 2008-05-07 Cytokinetics Inc Compos s, compositions et m thodes
EP1620092A4 (fr) 2003-05-07 2008-04-16 Cytokinetics Inc Composes, compositions et methodes
US20070032536A1 (en) 2003-05-15 2007-02-08 Xianping Qian Compounds, compositions and methods
RU2006138864A (ru) * 2004-04-06 2008-05-20 Чирон Корпорейшн (Us) Ингибиторы митотического кинезина
ES2311992T3 (es) * 2004-05-21 2009-02-16 Novartis Vaccines And Diagnostics, Inc. Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.
BRPI0510929A (pt) * 2004-06-18 2007-07-17 Chiron Corp derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer
EP2275412A1 (fr) * 2004-10-19 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Dérivés d'indole et de benzimidazole
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
TW200800951A (en) * 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
EP2091926B1 (fr) * 2006-11-13 2015-10-21 Novartis AG Composés de pyrazole et de triazole substitués comme inhibiteurs de ksp

Also Published As

Publication number Publication date
CO6382171A2 (es) 2012-02-15
EA017748B1 (ru) 2013-02-28
BRPI0719002A2 (pt) 2013-12-17
ZA200902940B (en) 2010-05-26
TW200831480A (en) 2008-08-01
DOP2009000106A (es) 2009-05-31
NO20092226L (no) 2009-08-12
US7902240B2 (en) 2011-03-08
ES2557478T3 (es) 2016-01-26
CA2668661A1 (fr) 2008-05-29
CN101558049A (zh) 2009-10-14
JP5264755B2 (ja) 2013-08-14
CL2007003272A1 (es) 2008-03-24
AU2007323998B2 (en) 2011-09-22
KR20090081020A (ko) 2009-07-27
NI200900084A (es) 2010-01-29
PE20081169A1 (es) 2008-09-24
EP2091926A1 (fr) 2009-08-26
GEP20125389B (en) 2012-01-25
CR10787A (es) 2009-07-02
MX2009005071A (es) 2009-05-25
HN2009000968A (es) 2011-10-25
US20100034813A1 (en) 2010-02-11
SMAP200900045A (it) 2009-07-14
TN2009000178A1 (en) 2010-10-18
EA200900631A1 (ru) 2009-12-30
JP2010509365A (ja) 2010-03-25
US20080200462A1 (en) 2008-08-21
UA97256C2 (ru) 2012-01-25
ECSP099326A (es) 2009-06-30
CN101558049B (zh) 2012-08-15
AR063805A1 (es) 2009-02-18
AU2007323998A1 (en) 2008-05-29
NZ576640A (en) 2011-10-28
EP2091926B1 (fr) 2015-10-21
US8129358B2 (en) 2012-03-06
WO2008063912A1 (fr) 2008-05-29
GT200900122A (es) 2011-09-14
SMP200900045B (it) 2010-03-01
IL198471A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
MA30959B1 (fr) Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA31080B1 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5.
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA30781B1 (fr) Inhibiteur de kinase
MA29909B1 (fr) Derives de pyridazine
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
TN2009000544A1 (fr) Derives de benzimidazole
MA31580B1 (fr) Derives de bicyclolactames substitués
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
TW200612958A (en) Substituted imidazole derivatives
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
TW200833675A (en) Nicotinamide derivatives
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA32151B1 (fr) Derives de 2-aza-bicyclo[2.2.1]heptane
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MA30819B1 (fr) Nouvelle diphenylazetidinone substituee par l'acide piperazin-1-sulfonique et presentant des proprietes pharmacologiques ameliorees
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
WO2007109578A3 (fr) Gamma lactames substitues en tant qu'agents therapeutiques
WO2007126900A3 (fr) Agents antifongiques
MA63589B1 (fr) Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle